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The authors developed a simple, sensitive and specific liquid chromatography-tandem mass spectrometry 
(LC–MS/MS) method for the quantification of naratriptan (NP) in human plasma using naratriptan-d3 
(NPD3) as an internal standard (IS). Chromatographic separation was performed on a Zorbax SB-C18, 
75 x 4.6 mm, 3.5 mm column with an isocratic mobile phase composed of 0.1% formic acid : acetonitrile 
(50:50 v/v), at a flow-rate of 0.6 mL/min. NP and NPD3 were detected with proton adducts at m/z 
336.5→98.0 and 339.4→101.0 in selected reaction monitoring (SRM) positive mode, respectively. 
The liquid-liquid extraction method was used to extract the NP and NPD3. This method was validated 
over a linear concentration range of 0.1-25.0 ng/mL with a correlation coefficient of (r2) ≥ 0.9998. The 
Intra-day and Interday precision was found to be 1.8 to 3.6%, and 2.3 to 2.6%, and accuracy to be 
101.7- 104.2% and 101.8 to 102.9%, respectively. NP was found to be stable throughout freeze-thaw 
(three cycles), bench top and auto sampler stability studies. This method was successfully applied for 
the analysis of plasma samples following oral administration of NP (2.5 mg) in 31 healthy Indian male 
human volunteers under fasting conditions.
Uniterms: Liquid chromatography/quantitative analysis. Mass spectrometry/quantitative analysis. 
Naratriptan/determination/human plasma.
Os autores desenvolveram um método simples, sensível e específico de cromatografia líquida-
espectrometria de massa-tandem (LC-MS/MS) para a quantificação de naratriptan (NP) em plasma 
humano empregando naratriptan-d3 (NPD3) como padrão interno de referência (IS). A separação 
cromatográfica foi realizada em coluna Zorbax SB-C18, 75 x 4,6 mm, 3,5 µm com fase móvel isocrática 
composta por 0,1% ácido fórmico : acetronitrila (50:50 v/v) e taxa de fluxo de 0,6 mL/min. NP e NPD3 
foram detectados com adutos de prótons a m/z 336.5→98.0 e 339.4→101.0 in em modo positivo do tipo  
monitoramento de reação selecionada (SRM), respectivamente. Extração líquido-líquido foi empregada 
para extrair NP e NPD3, sendo o método validado para uma faixa linear de concentração de 0,1-25,0 ng/mL 
resultando em coeficiente de correlação (r2) ≥ 0,9998. A variação intra e interdia observada para precisão 
foi de 1,8 a 3,6% e 2,3 a 2,6%, respectivamente; para exatidão a variação foi de 101,7 a 104,2% e 101,8 a 
102,9%, respectivamente. O NP se mostrou estável frente a processos de congelamento-descongelamento 
(3 ciclos), e estudos de estabilidade de bancada e amostragem automática. O método desenvolvido foi 
aplicado com sucesso para a análise de amostras de plasma após a administração oral de 2,5 mg de 
NP em 31 voluntários humanos, de nacionalidade indiana, sexo masculino, sob condições aceleradas.
Unitermos: Cromatografia líquida/análise quantitativa. Espectrometria de massa/análise quantitativa. 
Naratriptan/determinação/plasma humano.
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INTRODUCTION
NP is chemically known as N-methyl-2-�3-(1-meth-
ylpiperidin-4-yl)-1H-indol-5-yl] ethane sulfonamide. The 
molecular formula is C17H25N3O2S, which corresponds to 
a molecular weight of 335.47. NP is a triptan drug used 
for the treatment of migraine headaches, and is a selec-
tive 5-hydroxytryptamine 1 receptor subtype agonist. It is 
well absorbed (74% oral bioavailability with peak plasma 
concentrations after 2-5 hours) having 28-31% protein 
binding, and is metabolized by a wide range of cytochrome 
P450 isoenzymes into a number of inactive metabolites, 
and has a 5-8 hour half life (Fuseau et al., 1997).
Several techniques such as fluorometry and liquid 
chromatography (LC) methods have been reported in the 
literature for the quantitative estimation of NP in biologi-
cal fluids (Vishwanathan et al., 2000; Ptacek et al., 2009; 
Dulery et al., 1997; Gueorguieva et al., 2005). Dulery et al. 
(1997) developed a method in rabbit plasma, using a liquid 
chromatographic-electrospray-mass spectrometric assay 
for the determination sumatriptan and naratriptan. To date, 
only a few methods have been developed in human plasma 
for quantification of NP (Vishwanathan et al., 2000; Ptacek 
et al., 2009; Dulery et al., 1997; Gueorguieva et al., 2005) 
by LC-MS/MS. Vishwanathan, Bartlett, Stewart (2000) 
developed a method for determination of antimigraine 
compounds rizatriptan, zolmitriptan, naratriptan and 
sumatriptan in human serum by liquid chromatography 
(LC MS/MS) with a solid phase extraction method, and 
observed good linearity between the concentration ranges 
of 1.0 - 100.0 ng/mL. However, the extraction method is 
expensive for large sample analysis.
The purpose of this investigation was to develop a 
simple, sensitive, selective and reproducible analytical 
method for the quantitative estimation of NP in a small vol-
ume of human plasma using deuterated internal standard. 
It is also envisaged that this method will be able to provide 
an efficient solution for pharmacokinetic, bioavailability 
or bioequivalence studies of NP.
MATERIALS AND METHODS
Materials
Naratriptan hydrochloride was obtained from APL 
Research, India, and naratriptan–d3 hydrochloride was 
obtained from Torronto Research Chemicals, Ontario, 
Canada. Analytical grade sodium carbonate, tertiary butyl 
methyl ether, formic acid and acetonitrile were purchased 
from SD fine chemical Ltd, Mumbai, India. Human plasma 
(K2EDTA) was purchased from the Navjeevan blood bank, 
Hyderabad, India. Double distilled water was used for all 
the experiments.
Instrumentation and detection
The HPLC system (1200 series, Agilent technolo-
gies, Waldbronn, Germany) was employed. A Mass spec-
trometer API 4000 triple quadrupole instrument (ABI-
SCIEX, Toronto, Canada) was used.Turbo ion spray 
positive mode with unit resolution, SRM was used for 
detection. For NP, �M+H]+ (m/z 336.5) was monitored as 
the precursor ion and a fragment at m/z 98.0 was chosen 
as the product ion. For NPD3, the �M+H]+ (m/z 339.4) 
was monitored as the precursor ion and a fragment at m/z 
101.0 was monitored as the product ion. Mass parameters 
were optimized as source temperature 600 °C, nebulizer 
gas 25 psi, heater gas 35 psi, curtain gas 20 psi, CAD 
gas 5 psi (nitrogen), ion spray voltage 5500 V, source 
flow rate 600 µL/min without split, entrance potential 
10 V, declustering potential 40 V, collision energy 16 V, 
and collision cell exit potential 6 V for both analyte and 
internal standard.
Chromatographic conditions
A Zorbax SB-C18, 75 × 4.6 mm, 3.5 µm, was se-
lected as the analytical column. The mobile phase compo-
sition was 0.1% formic acid: acetonitrile (50:50 v/v). The 
flow rate of the mobile phase was set at 0.6 mL/min. The 
column temperature was set at 50 °C. NPD3 was used as 
the appropriate internal standard. The retention time of NP 
and NPD3 were found to be 1.2 ± 0.2 min, respectively 
with a total run-time of 2 min for each sample.
Preparation of standards and quality control (QC) 
samples
Standard stock solutions of NP (100.0 µg/mL), and 
NPD3 (100.0 µg/mL) were prepared in methanol. NPD3 
dilution (250.0 ng/mL) was prepared in 50% acetonitrile 
from NPD3 standard stock solution. Standard and spik-
ing solutions were stored under refrigerator conditions 
(2-8 °C) until analysis. Standard stock solutions were 
added to drug-free human plasma to obtain NP concentra-
tion levels of 0.1, 0.2, 0.5, 1.0, 5.0, 10.0, 15.0, 20.0 and 
25.0 ng/mL for analytical standard, and of 0.1, 0.3, 7.5, 
17.5 ng/mL for quality control standards, and stored in 
a freezer (-30 °C) until analysis. The aqueous standards 
were prepared in reconstitution solution of acetonitrile: 
0.1% formic acid (50:50 v\v) and stored under refrigerator 
conditions (2-8 °C) for validation exercises until analysis.
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Sample preparation
Liquid-liquid extraction was used to isolate NP and 
NPD3 from human plasma. A volume of 50 µl of NPD3 
(30.0 ng/mL) and 250 µL of plasma sample (respective 
concentration) were added to polypropylene tubes, vor-
texed briefly and placed in an ice bath. This process was 
followed by addition of 250 µL of 0.5 N sodium carbonate, 
2.5 mL of extraction solvent (tertiary butyl methyl ether) 
and vortexed for approximately 10 min. Further samples 
were centrifuged at 4000 rpm for 5 min at 4 °C. Superna-
tant from each sample was transferred into polypropylene 
tubes and evaporated to dryness under nitrogen at 40 °C. 
Finally, dried residue from each tube was reconstituted 
with 250 µL of reconstitution solution (acetonitrile: 0.1% 
formic acid (50:50 v/v) and vortexed briefly. Subsequently, 
20 µL of sample from each tube was transferred into auto 
sampler vials and injected into the LC-MS/MS.
Recovery
The extraction recovery of NP and NPD3 from hu-
man plasma was determined by analyzing quality control 
samples. Recovery at three concentrations (0.3, 7.5 and 
17.5 ng/mL) was determined by comparing peak areas ob-
tained from the plasma sample, and the standard solution 
spiked with the blank plasma residue. A recovery of more 
than 50% was considered adequate to attain the required 
sensitivity.
Limit of quantification (LOQ)
Peak response (peak area) was determined in blank 
plasma samples (six replicates from different plasma) and 
in spiked LOQ sample prepared from the same plasma. 
The peak area of blank samples should be no greater than 
20% of the mean peak area of LOQ of NP, and no greater 
than 5% of NPD3. The precision and mean accuracy of 
the back calculated LOQ replicate concentrations must be 
≤ 20 and ± 20 %, respectively.
Analytical curves, regression model
The analytical curves were constructed using values 
ranging from 0.1 to 25.0 ng/mL of NP in human plasma. 
Calibration curves were obtained by the weighted qua-
dratic model with the log-transformed regression model. 
The ratio of NP peak area to NPD3 peak area was plotted 
against NP concentration in ng/mL. The suitability of the 
calibration curve was confirmed by back-calculating the 
concentrations of the calibration standards.
Log y = a log (x2) +b log (x) + c
y = peak area ratio (PAR) of NP to NPD3
x = concentration (ng/mL) of NP in plasma.
Coefficients a, b and c, the coefficient of determina-
tion (r2) and x was calculated using weighted 1 quadratic 
model with log-transformed regression analysis.
Calibration curve standards and quality control 
samples
Calibration curve standard samples and quality 
control samples were prepared in replicate (n=6) for analy-
sis. The correlation coefficient (>0.9998) was obtained 
by using the quadratic model with the log-transformed 
regression model across the whole range of tested con-
centrations.
Precision and accuracy
Precision and accuracy for the back-calculated con-
centrations of the calibration points should be within ± 
15% of their nominal values. For LOQ however, precision 
and accuracy should be within ± 20%.
Stability (Freeze- thaw, Auto sampler, Bench top, 
Re-injection, Long term)
Low quality control and high quality control sam-
ples (n=6) were retrieved from the deep freezer after three 
freeze-thaw cycles according to the clinical protocol. 
Samples were stored at -30 oC in three cycles of 24, 36 and 
48 h. In addition, the long-term stability of NP in quality 
control samples was also evaluated by analysis after 100 
days of storage at −30 oC. Autosampler stability was stu-
died following a 101.5 h storage period in the autosampler 
tray. Bench-top stability was studied for a 25 h period. 
Re-injection stability was proved for one reinjection. Sta-
bility samples were processed and extracted along with the 
freshly spiked calibration curve standards. The precision 
and accuracy for the stability samples must be within 15 
and ± 15% of their nominal concentrations, respectively.
Matrix effect
The matrix effect was performed in order to deter-
mine the matrix effect (ion suppression/ ion enhancement) 
qualitatively on different lots of blank plasma (6 lots from 
K2EDTA blank plasma), using triplicate analysis at low 
and high concentrations, which were extracted and injec-
ted as per method. The ion suppression matrix effect was 
evaluated by injecting reagent blank, different lots of blank 
B.R. Challa, B.Z.S. Awen, B.R. Chandu, R.P. Shaik16
plasma (6 lots from K2 EDTA blank plasma) of extracted 
blank matrix while the aqueous standard was infused. No 
significant matrix effect was observed.
Column to column reproducibility
Column to column reproducibility was determined 
by injecting analytical standards, matrix blank and QC 
standards on different columns. The results showed good 
reproducibility.
Standard and stock solution stability
Standard stock solution stability at room temperature 
in white light under laboratory conditions and refrigerated 
conditions for NP and NPD3 was performed as part of the 
method development process. The results showed good 
stability for 57 days under refrigerated conditions.
Analysis of patient samples
The bio-analytical method described above was 
used to determine NP concentrations in plasma following 
oral administration in healthy human volunteers. These 
volunteers were contracted in APL Research Pvt. Ltd., 
Hyderabad, India... and each of the 31 healthy volunteers 
was administered a 2.5 mg dose (one 2.5 mg tablet) by the 
oral route with 240 mL of drinking water. The reference 
product Amerge tablets (GSK) 2.5 mg and test product NP 
tablet (Test tablet) 2.5 mg were used. The study protocol 
was approved by the IEC (Institutional Ethics Committee) 
as per ICMR guidelines (Indian Council of Medical Re-
search). Blood samples were collected at pre-dose (0hr), 
5 minutes prior to dosing, followed by further sample 
taken at 0.5, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.33, 3.67, 4, 
4.5, 5, 6, 8, 10, 12, 14, 18, 24 and 30 hours. After dosing, 
5 mL of blood was taken at each collection and placed in 
vacutainers containing K2EDTA. Collections were taken 
for 44 (22 time points for test and reference, respectively) 
time points using centrifugation 3200 rpm at 10 °C for 
10 min, and storage at -30 °C until sample analysis. Test 
and reference were administered separately to the same 
human volunteers under fasting conditions with proper 
wash-out periods as per the protocol approved by IEC.
Pharmacokinetics and statistical analysis
Pharmacokinetics parameters for the human plasma 
samples were calculated by a non-compartmental statistics 
model using WinNon-Lin5.0 software (Pharsight, USA). 
Plasma samples were taken for a period of 3 to 5 times 
the terminal elimination half-life (t1/2), considered the area 
under the concentration time curve (AUC) ratio higher 
than 80%, as per FDA guidelines. Plasma NP concentra-
tion–time profiles were visually inspected, and Cmax and 
Tmax values were determined. The AUC0–t was obtained 
by the trapezoidal method. AUC0–∞ was calculated up to 
the last measureable concentration and extrapolations 
were obtained using the last measureable concentration, 
and the terminal elimination rate constant (Ke). Ke was 
estimated from the slope of the terminal exponential 
phase of the plasma of the NP concentration–time curve 
by the linear regression method. The terminal elimination 
half-life t1/2, was then calculated as 0.693/Ke. Regarding 
AUC0–t, AUC0–∞ and Cmax bioequivalence was assessed 
by analysis of variance (ANOVA) and by calculating the 
standard 90% confidence intervals (90% CIs) of the ratio’s 
test/reference (logarithmically transformed data). The 
bioequivalence was considered when the ratio of averages 
of log transformed data was within 80–125% for AUC0–t 
, AUC0–∞ and Cmax.
RESULTS AND DISCUSSION
Method development and validation
LC-MS/MS is one of the most powerful analytical 
tools used in clinical pharmacokinetics given its selec-
tivity, sensitivity and reproducibility. The goal of this 
work was to develop and validate a simple, sensitive and 
rapid assay method for quantitative determination of NP 
from plasma samples. A simple Liquid-liquid extraction 
technique was utilized for extraction of NP and NPD3 
from the plasma samples. Chromatographic conditions, 
particularly the composition and nature of the mobile 
phase, were optimized through several earlier trials to 
achieve best resolution and to increase the signal of NP and 
NPD3. MS optimization was performed by direct infusion 
of solutions of both NP and NPD3 into the ESI source of 
the mass spectrometer. The critical parameters in the ESI 
source include the needle (ESI) voltage, which is directly 
related to the charged droplet formation and to the amount 
of gaseous ions formed. Capillary voltage was related to 
the gaseous ion guidance to the inside of the MS and is the 
last barrier between the atmospheric pressure and the high 
vacuum of the mass spectrometer. Other parameters, such 
as the nebulizer and heater gases, were optimized to obtain 
a better spray shape, resulting in improved ionization and 
droplet drying to form the protonated ionic NP and NPD3 
molecules (Figures 1a, 1b). A CAD product ion spectrum 
for NP and NPD3 yielded high-abundance fragment ions 
of m/z 98 and m/z 101, respectively (Figures 2, 3). After the 
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SRM channels were tuned, the mobile phase was changed 
from an aqueous phase to a more organic phase with acid 
dopant to obtain a fast and selective LC method. Good 
separation and elution were achieved using 0.1% formic 
acid: acetonitrile (50:50 v/v) as the mobile phase, at a 
flow-rate of 0.6 mL/min with a 10 µL injection volume.
FIGURE 1 - Chemical structures of  Naratriptan and Naratriptan –D3 
FIGURE 2 - Mass spectra of the Naratriptan Q1, Q3.
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Selectivity
The analysis of NP and NPD3 using MRM function 
was highly selective with no interfering compounds (Fi-
gure 4A). Chromatograms obtained from plasma spiked 
with NPD3 (30.0 ng/mL) are shown in Figure 4B, and 
spiked with NP (0.1 ng/mL) and NPD3 (30.0 ng/mL) are 
shown in Figure 4C.
Matrix effect
To predict the variability of matrix effects in samples 
from individual subjects, the matrix effect was quantified 
by determining the matrix factor, which was calculated 
as follows.
 
Peak response ratio in the presence of extracted matrix
Matrix Factor = –––––––––––––––––––––––––––––––––––––––––––––
 
Peak response ratio in aqueous standards
Six lots of blank biological matrix were spiked, each 
in triplicate, with the aqueous standard at the mid QC level, 
and compared against aqueous standards of the same con-
centration in alternate injections. The overall precision of 
the matrix factor is expressed as coefficient of variation 
(% CV) and was determined to be ≤ 15% for NP.
Linearity
Calibration curves were plotted as the peak area ra-
FIGURE 3 - Mass spectra of the Naratriptan -d3 Q1, Q3.
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FIGURE 4A - SRM chromatograms of naratriptan and 
naratriptan-d3  in blank human plasma.
FIGURE 4B - Spiked human plasma containing 30.0 ng/mL 
naratriptan-d3 �Blank+IS].
FIGURE 4C - spiked human plasma containing 0.1 ng/mL 
naratriptan and 30.0 ng/mL naratriptan-d3 �LLOQ].
tio (NP and NPD3) versus NP concentration. Calibration 
was found to be linear over the concentration range of 
0.1 - 25.0 ng/mL. The R.S.Ds was less than 15%, and the 
accuracy ranged from 98.7 to 101.5%. The determination 
coefficients (r2) were greater than 0.9998 for all curves 
(Table I).












0.1 0.1 ± 0.0 1.0 99.0
0.2 0.2 ± 0.0 3.0 101.5
0.5 0.4 ± 0.0 2.4 99.0
1.0 1.1 ± 0.1 1.3 100.7
5.0 5.1 ± 0.1 1.3 100.1
10.0 9.8 ± 0.1 1.3 98.7
15.0 15.1 ± 0.2 1.0 100.3
20.0 20.1 ± 0.3 1.3 100.4
25.0 25.1 ± 0.3 1.1 100.2
a �Standard deviation/mean concentration measured] x 100.
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Precision and accuracy of quality control 
standards
The quantitative accuracy and precision of the as-
say was evaluated on an inter-assay basis, using prepared 
QC standards at three concentrations spanning the range 
of the analytical standard curve. Precision is expressed 
as % CV. Precision and accuracy for this method was 
controlled by calculating the intra and inter-batch varia-
tions at three concentrations (0.3, 7.5 and 17.5 ng/mL) of 
QC samples in six replicates. As shown in Table II, Intra 
and inter-day CV% ranged from 1.8 to 3.6 and from 2.3 
to 2.6%, respectively, while Intra and inter-day accuracy 
ranged from 101.7 to 104.2% and from 101.0 to 102.9%, 
respectively, for NP. These results indicate the adequate 
reliability and reproducibility of this method within the 
analytical range.
Stability (Freeze- thaw, Auto sampler, Room 
temperature, Long term)
Quantification of NP in plasma subjected to 3 free-
ze–thaw (-30 oC to room temperature) cycles verified the 
stability of the analyte. No significant degradation of NP 
was observed even after a 101.5 h storage period in the 
autosampler tray, and the final concentrations of NP ranged 
from 97 to 104%. In addition, the long-term stability of NP 
in QC samples after 100 days of storage at -30 oC was also 
evaluated. The concentrations ranged from 99 to 106% 
(Table III). These results confirmed the stability of NP in 
human plasma for at least 100 days at -30 oC.
Recovery
The recovery following sample preparation using the 
Liquid-liquid extraction method with tertiary butyl methyl 
ether was calculated by comparing the peak area ratios of 
NP in plasma samples with the peak area ratios of solvent 
samples, and was estimated at control levels of NP. The re-
covery of NP, determined at three different concentrations 
0.3, 7.5 and 17.5 ng/mL, were found to be 67.8, 70.5 and 
71.7%, respectively. The overall average recovery of NP 
and NPD3 were found to be 70.02 and 70.49%.
Limit of detection (LOD)
The limit of detection was determined using aqueous 
solutions. For NP, 10 mL of 5 pg/mL solution was injected, 
yielding 0.05 pg/mL.
Application to biological samples
The above-validated method was used in the de-
termination of NP in plasma samples for establishing 
the bioequivalence of a single 2.5 mg dose (one 2.5 mg 
tablet) in 31 healthy volunteers. Typical plasma con-
centrations versus time profiles are shown in Fig. 5. All 
the plasma concentrations of NP were within the stan-
dard curve region and remained above the 0.1 ng/mL 
LOQ for the entire sampling period. The observed ma-
ximum plasma concentration (Cmax) for the standard and 
test were 94.5±3.36 and 92.0±3.33 ng/mL, respectively. 
FIGURE 5 - Mean plasma concentrations of test vs. reference 
after a 2.5 mg dose (one 2.5 mg Tablet) single oral dose (31 
healthy volunteers).












R.S.D.a (%CV) Accuracy %
0.3 0.3±0.0 3.6 101.7 0.3 ± 0.0 2.6 101.0
7.5 7.8±0.1 1.8 104.0 7.6 ± 0.2 2.3 101.2
17.5 18.2±0.5 2.7 104.2 18.0 ± 0.4 2.4 102.9
a �Standard deviation/mean concentration measured] x 100.
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The corresponding time of maximum concentration (Tmax) 
for reference and test were found to be 2.67 and 2.67 hr, 
respectively. The value of the area under the curve from 
time 0 to the last sampling time (AUC0–t) for the stan-
dard and test were found to be 103.04 ± 2.86 and 102.08 
± 2.89 ng.hr/mL, respectively. The area under the curve from 
0 to ∞ (AUC0–∞) was 108.48 ng.h/mL for the standard and 
107.97 ng.hr/mL for the test. The elimination half-
life (t1/2) was 7.05 hr for the reference drug and 7.45 hr 
for the generic drug. In addition, the mean ratio of 
AUC0–t/AUC0–∞ was higher than 90%, in accordance 
to the Food and Drug Administration Bioequivalence 
Guideline. The test/reference ratio (T/R) and 90% confi-
dence intervals (90 CIs) for overall analysis fell within the 
previously stipulated range (80–125%). The T/R ratio and 
90 CIs (in parenthesis) were 97.31% for Cmax, 99.06% 
for AUC0–t , and 99.53% for AUC0–∞. Therefore, it can 
be concluded that the two NP formulations (reference and 
test) analyzed are bioequivalent.
CONCLUSION
The proposed method offers significant advantages 
over previously reported methods in terms of simplicity, 
sensitivity, selectivity, ruggedness and reproducibility. The 
major advantage of this method is the use of a minimal 
volume of 250 μL plasma sample that greatly facilitates 
blood sample collection. In addition, this method has 
shown a wider linearity range from 0.1 to 25.0 ng/mL. No 
side effects were observed during or after the study by the 
volunteers who participated. Limit of detection (LOD) was 
proved for 0.05 pg/mL. NP and NPD3 were eluted within 
1.2 ± 0.2 min with a total run time of 2 min. This method 
was fully validated as per FDA guidelines and successfully 
applied in bioequivalence studies to evaluate the plasma 
concentrations of NP in healthy human volunteers.




Room temperature stability Processed sample stability Long-term stability Freeze and thaw stability





























0.3 0.3 ± 0.01 3.5 0.3 ± 0.0 3.54 0.3 ± 0.0 2.6 0.3 ± 0.0 3.01
17.5 17.9 ± 0.1 1.1 17.7 ± 0.4 2.10 17.8 ± 0.2 1.16 17.63± 0.2 0.93
a �Standard deviation/mean concentration measured] x 100.
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